Aadi Bioscience Stock Buy or Sell? AADI Stocks Forecast

Market Capitalization: 176 864 000 $
EBITDA: -59 277 000 $
Price to Earnings: 1.597
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 18.23
Trailing PE: 1.597
Forward PE: -
Shares Outstanding: 24395100

Aadi Bioscience Stock Buy or Sell? AADI Stocks Analytic Forecasts

April 1, 2023 (05:33)

Aadi Bioscience, Inc. (AADI) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the AADI stock market. Experts share their opinions on what to expect from the Aadi Bioscience, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Aadi Bioscience stocks.

Aadi Bioscience, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy AADI Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Avisol Capital Partners and is titled

“Aadi Bioscience: Commercial Stage With Large Market In Label Expansion”

is published on March 6 (2023) and has 1 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • AADI is a commercial stage company with a potential label expansion ahead.
  • It is adequately funded, run by expert management, and has a major catalyst next year.
  • All told, AADI looks good.

The author starts his analytic review with the following:

Aadi Bioscience (NASDAQ:AADI) is a commercial stage oncology drug developer working with the mTOR pathway. Lead asset FYARRO (nab-sirolimus) is an albumin-bound sirolimus approved for advanced malignant PEComa (perivascular epithelioid cell tumors), a type of rare cancer occurring in the soft tissues of internal organs. The company’s exclusive focus is on cancers that are highly mTOR dependent, and it uses a nanoparticle albumin-based (nab) platform validated by paclitaxel. Fyarro is licensed from Celgene, and in the initial years, Celgene also funded the company. The company was founded and is led by Neil Desai, PhD, a co-creator of abraxane, along with Patrick Soon-Shiong, at Abraxis.

This author is very popular among the auditory. He has 16485 followers

Avisol Capital Partners is the contributor of experts community since 2017 and has a great number of published articles – 1923.

One more noteworthy article is written by Jonathan Faison under the title

“Aadi Bioscience: Taking mTOR Inhibition To The Next Level”

on September 21 (2022) and has 1 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add AADI stocks to your investment portfolio or not, and helps to work out your own Aadi Bioscience stock selling strategies:

  • Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals.
  • Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression.
  • Registrational data for Fyarro in PEComa showed impressive durability which is now translating into encouraging launch metrics out of the gate.
  • Institutional clustering and extent of leadership’s relevant prior experience both stick out as green flags to my eyes.
  • AADI is a Buy in my view, with key catalyst being initial readout of PRECISION1 trial in 2023. Risks include dilution in the near to medium term, disappointing data and delays in timelines.

Jonathan Faison starts analysis with such words:

Shares of precision oncology upstart Aadi Bioscience (NASDAQ:AADI) have lost half of their value since reverse merger with Aerpio Pharmaceuticals was closed in August of 2021. Year to date return is slightly less negative at -45%.

This author is very popular among the auditory. He has 16503 followers

Jonathan Faison is the contributor of experts community since 2011. Has published at least 851 articles.

Another analysis presented by Terry Chrisomalis came out on November 25 (2021). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for AADI stocks. It sounds like

“Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning”

Article has got 4 likes at the moment and forecasting Strong Bullish trend of the market.

Summarizing the information presented in the review concerning the Aadi Bioscience, Inc., the expert says the following:

  • Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa.
  • Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients.
  • Further expansion of ABI-009 can be achieved with targeting other cancer subpopulations that have the mTOR pathway.
  • Aadi Bioscience had $161.4 million in cash and cash equivalents as of September 30, 2021; enough cash to fund operations into 2024.

And here, what comes first:

Aadi Bioscience (NASDAQ:AADI) received FDA approval for its drug Fyarro (ABI-009), which was approved to treat patients with a rare ultra sarcoma known as a PEComa. It is a small population of patients, but Fyarro is the first drug approved for it. However, I believe that this initial approval sets up for greater potential based on a possible expansion of using the mTOR pathway towards other targets. The goal is to file an IND to start two new studies. These two new studies are expected to be tumor-agnostic ones. Meaning, they will use ABI-009 to go after genomic alterations regardless of tumor type. In other words, the main goal is to target TSC1 and TSC2 genomic alterations. This will help Aadi to go after a larger group of patients, not just 300 patients in the United States with PEComa. With proof of concept and FDA approval of Fyarro, there is an opportunity to increase the drug’s reach towards other genomic alteration pathway targets. I believe this could set up the company for increased revenue, should it be able to achieve positive results in these other mTOR gene pathways.

This author is very popular among the auditory. He has 10591 followers.

Terry Chrisomalis is the contributor of experts community since 2013 and has at least 973 analytic reviews published.

The Share Price of Aadi Bioscience, Inc. (AADI) for now

What analysts predict: $42.5
52-week high/low: $18.47 / $7

50/200 Day Moving Average: $10.69 / $12.46

The average stock price over the previous 50/200 days. For Aadi Bioscience stocks, the 50-day moving average is the resistance level for now. For AADI stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for AADI stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Buy or Sell LLY shares? Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 23, 2023
84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.

If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs

Buy or Sell JNJ shares? If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs
March 10, 2023
Recession is coming and with it plenty of scary headlines about crashing stock prices and financial doom.